title: Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
abstract: Stent thrombosis is a morbid complication after percutaneous coronary intervention. Dual antiplatelet therapy significantly reduces stent thrombosis risk and forms currently the basis in acute ST elevation myocardial infarction pharmacologic treatment. The introduction of clopidogrel has made a major advance in the acute coronary syndrome treatment. However, there is growing evidence about failure in antiplatelet response after clopidogrel, which may lead to subsequent risk of future thrombotic events. The antiplatelet inhibitory effect of clopidogrel varies widely among individuals. High on-treatment platelet reactivity has been repeatedly associated with a hazard for cardiovascular events, including stent thrombosis. Laboratory monitoring of antiplatelet therapy efficacy may help identify patients with insufficient antiplatelet response. Prasugrel therapy was repeatedly described as an effective method to overcome clopidogrel resistance. We report a case of diabetic patient in whom myocardial reinfarction due to stent thrombosis developed. Clopidogrel resistance was detected in this patient using light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation assessment. After prasugrel administration, no other ischemic event occurred, and patient was released to outpatient care in good general condition.
authors.affiliation: Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic. Electronic address: matej.samos@gmail.com.
authors.forename: Matej
authors.initials: M
authors.lastname: Samoš
authors.affiliation: National Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Radoslava
authors.initials: R
authors.lastname: Šimonová
authors.affiliation: Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Frantisek
authors.initials: F
authors.lastname: Kovář
authors.affiliation: National Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Lukas
authors.initials: L
authors.lastname: Duraj
authors.affiliation: Hemomedika, Center of Thrombosis and Hemostasis, Martin, Slovak Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Fedorová
authors.affiliation: Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Peter
authors.initials: P
authors.lastname: Galajda
authors.affiliation: Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Staško
authors.affiliation: National Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Marian
authors.initials: M
authors.lastname: Fedor
authors.affiliation: National Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Peter
authors.initials: P
authors.lastname: Kubisz
authors.affiliation: Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
authors.forename: Marian
authors.initials: M
authors.lastname: Mokáň
mesh_terms: D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D017023:Coronary Angiography; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004351:Drug Resistance; D004562:Electrocardiography; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects*; D013876:Thiophenes / Q000627:therapeutic use; D013927:Thrombosis / Q000150:complications* / Q000188:drug therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D006493:Heparin; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine; D001241:Aspirin